SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS

Brausi M., Oddens J., Sylvester R., Bono A., Gontero P., Turkeri L.

Annual Meeting of the American-Urological-Association (AUA), California, United States Of America, 4 - 08 May 2013, vol.189, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 189
  • Doi Number: 10.1016/j.juro.2013.02.3004
  • City: California
  • Country: United States Of America
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No